歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01672 歌礼制药-B

休市中 09-04 16:08:03

10.090

-0.240

-2.32%

最高10.640	最低10.090	成交量184.00万
今开10.400	昨收10.330	日振幅5.32%
总市值106.15亿	流通市值106.15亿	总股本10.52亿
成交额1,893万	换手率0.17%	流通股本10.52亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01672","market":"HK","secType":"STK","nameCN":"歌礼制药-B","latestPrice":10.09,"timestamp":1788509283003,"preClose":10.33,"halted":0,"volume":1839964,"delay":0,"changeRate":-0.023233301064859654,"floatShares":1052000000,"shares":1052000000,"eps":-0.43271534245501225,"marketStatus":"休市中","change":-0.24,"latestTime":"09-04 16:08:03","open":10.4,"high":10.64,"low":10.09,"amount":18925388,"amplitude":0.053243,"askPrice":10.09,"askSize":4000,"bidPrice":10.08,"bidSize":16000,"shortable":3,"etf":0,"ttmEps":-0.6839346007292115,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788744600000},"marketStatusCode":7,"adr":0,"listingDate":1533052800000,"exchange":"SEHK","adjPreClose":10.33,"openAndCloseTimeList":[[1788485400000,1788494400000],[1788498000000,1788508800000]],"volumeRatio":0.939643,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01672","defaultTab":"news","newsList":[{"id":"2664233915","title":"上交所宣布调整沪港通下港股通标的，调入百度、歌礼制药等54只，调出佑驾创新等15只。","url":"https://stock-news.laohu8.com/highlight/detail?id=2664233915","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664233915?lang=zh_cn&edition=full","pubTime":"2026-09-04 19:33","pubTimestamp":1788521612,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0173614495.USD","LU1048588211.SGD","LU0821914370.USD","LU0708995583.HKD","BK1575","LU1188198961.HKD","LU0456827905.SGD","LU0823426480.USD","LU0326950275.SGD","SG9999014674.SGD","TCHI","LU0164880469.USD","LU0630378692.HKD","LU0228367735.SGD","LU0051755006.USD","LU0359202008.SGD","LU0348825331.USD","LU0543330566.HKD","LU0164865239.USD","LU0762540952.USD","HK0000306685.HKD","LU0244354667.USD","LU0417516902.SGD","BK1144","SG9999002463.SGD","LU0762541174.USD","LU0197773673.USD","LU0052750758.USD","IE00B3M56506.USD","BK1574","BK1615","89888","LU0531971595.HKD","09888","HK0000320223.HKD","LU2039709279.SGD","LU1831875114.USD","LU0287142896.SGD","HK0000306701.USD","LU1328615791.USD","LU0197773160.USD","LU0630378429.USD","LU1115378108.SGD","LU0320764599.SGD","BK1588","LU0831093199.SGD","LU1481107354.HKD","LU1023057109.AUD","LU0315179316.USD","LU0039217434.USD","LU0871576103.HKD","LU0417516738.SGD","BK1609","SG9999002828.SGD","LU2778985437.USD","LU0588546209.SGD","LU0163747925.USD","BK1161","BK1095","LU0359201612.USD","LU1048596156.SGD","BK1587","LU0043850808.USD","LU0823426308.USD","BK1515","HK0000320264.USD","LU0307460666.USD","BIDU","02431","LU0856984785.SGD","01672","IE0034224299.USD","LU0463099449.HKD","LU0348735423.USD","LU0149721374.USD","LU0762542818.HKD","LU0819121731.USD","LU0359201885.HKD","LU0640798160.USD","LU2476274308.USD","LU0229945570.USD","LU0072462343.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664014829","title":"大行评级丨高盛：下调歌礼制药目标价至13.86港元，维持“中性”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2664014829","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664014829?lang=zh_cn&edition=full","pubTime":"2026-09-03 14:04","pubTimestamp":1788415446,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["01477","BK1191","01672","BK1515","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112769612","title":"歌礼制药-B更新2026年8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1112769612","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112769612?lang=zh_cn&edition=full","pubTime":"2026-09-03 10:36","pubTimestamp":1788402967,"startTime":"0","endTime":"0","summary":"歌礼制药有限公司于2026年9月3日披露了截至2026年8月31日止的证券变动月报表。公告显示，公司法定/注册股本无变化，仍为70亿股普通股，面值每股0.0001美元，法定/注册股本总额700,000美元。报告期末，公司已发行普通股总数为1,051,984,845股，库存股为5,784,210股，与上月底一致。歌礼制药-B于本报告期内继续符合香港联交所对公众持股量的相关规定。截至8月末，公司整体股本结构保持稳定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664898526","title":"歌礼制药-B早盘涨超8% ASC30用于长期体重管理的全球III期临床项目完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2664898526","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664898526?lang=zh_cn&edition=full","pubTime":"2026-09-02 10:13","pubTimestamp":1788315180,"startTime":"0","endTime":"0","summary":"模拟交易客户端歌礼制药-B早盘涨超8%，截至发稿，股价上涨8.07%，现报10.31港元，成交额926.46万港元。近日，歌礼制药-B发布公告，ASC30用于长期体重管理的全球III期临床项目已完成首例受试者给药。ASC30是一款歌礼专有的、正在临床研究中的每日一次口服小分子胰高血糖素样肽-1受体激动剂，开发用于长期体重管理和糖尿病治疗。公告称，歌礼制药-B预计将于2028年第三季度公布AURORA III期临床项目的顶线数据。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-02/doc-iniqkzma1311603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1161","01672","01477","BK1191","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664260860","title":"港股异动 | 歌礼制药-B(01672.HK)涨超5% ASC30用于长期体重管理的全球III期临床项目完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2664260860","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664260860?lang=zh_cn&edition=full","pubTime":"2026-09-02 09:49","pubTimestamp":1788313757,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","01672","BK1574","BK1161","01477","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663006583","title":"歌礼制药-B(01672)发布中期业绩 股东应占亏损3.2亿元 同比增加263.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663006583","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663006583?lang=zh_cn&edition=full","pubTime":"2026-08-31 21:24","pubTimestamp":1788182651,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布截至2026年6月30日止六个月业绩，该集团取得收入总额人民币5297.9万元，同比减少48.9%;研发成本3.42亿元，同比增加132.7%;公司权益股东应占亏损3.2亿元，同比增加263.5%;每股亏损30.74分。人体数据表明，ASC50有望成为同类首创及同类最佳口服小分子IL-17A抑制剂。ASC51为一款强效、选择性及每日一次口服STAT6降解剂并已具备向FDA 提交IND申请条件的候选药物。ASC52有望成为同类最佳IL-17AA、AF及FF口服环肽拮抗剂，预计将于2026年第四季度向FDA递交IND。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489861.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01672","BK1515","01477","BK1191","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162031632","title":"歌礼制药-B：董事会建议不派发中期股息","url":"https://stock-news.laohu8.com/highlight/detail?id=1162031632","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162031632?lang=zh_cn&edition=full","pubTime":"2026-08-31 21:18","pubTimestamp":1788182334,"startTime":"0","endTime":"0","summary":"歌礼制药-B（01672.HK）宣布，其董事会已决定不建议就中期业绩派发任何股息。这一决定反映出公司在当前阶段的财务策略与资本配置考量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","01672","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118188053","title":"歌礼制药-B2026年中期财报营收5,298万元，经调整净亏损3.20亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1118188053","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118188053?lang=zh_cn&edition=full","pubTime":"2026-08-31 21:17","pubTimestamp":1788182270,"startTime":"0","endTime":"0","summary":"本季度信息\n据公司公告披露，歌礼制药-B在截至2026年6月30日止六个月实现营收5,298万元，同比下降48.9%。经调整净亏损为3.20亿元，同比扩大263.5%。\n公告显示，研发成本约3.42亿元，同比大幅增长132.7%，主要系公司加大在代谢性疾病相关管线的投入。行政开支约3,080.3万元，同比下降28.9%，主要来自员工相关成本的减少。公司未在公告中披露具体毛利率及经营利润率，但经营成本结构显示，研发投入占比在报告期内进一步上升。\n此外，期内经营活动所用现金净额约3.27亿元，账面现金及现金等价物等共约23.05亿元，可支持公司运营至2029年。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"歌礼制药-B2026年中期财报营收5,298万元，经调整净亏损3.20亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142928380","title":"歌礼制药-B：口服小分子GLP-1激动剂ASC30全球III期试验完成首例给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1142928380","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142928380?lang=zh_cn&edition=full","pubTime":"2026-08-30 18:11","pubTimestamp":1788084713,"startTime":"0","endTime":"0","summary":"2026年8月30日，歌礼制药-B（01672）发布自愿性公告称，公司自主研发的每日一次口服小分子胰高血糖素样肽-1受体（GLP-1R）激动剂ASC30用于长期体重管理的全球III期临床项目已完成首例受试者给药。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663415150","title":"歌礼制药-B(01672)：每日一次口服小分子GLP-1受体激动剂ASC30用于长期体重管理的全球III期临床项目完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2663415150","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663415150?lang=zh_cn&edition=full","pubTime":"2026-08-30 18:08","pubTimestamp":1788084524,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，ASC30用于长期体重管理的全球III期临床项目已完成首例受试者给药。ASC30是一款歌礼专有的、正在临床研究中的每日一次口服小分子胰高血糖素样肽-1受体激动剂，开发用于长期体重管理和糖尿病治疗。歌礼预计将于2028年第三季度公布AURORA III期临床项目的顶线数据。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489037.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["JDOC","BK1515","01477","BK1191","01672","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661600092","title":"歌礼制药-B(01672)发盈警，预期中期股东应占亏损约3.197亿元 同比增加约263.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661600092","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661600092?lang=zh_cn&edition=full","pubTime":"2026-08-21 20:20","pubTimestamp":1787314847,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，本集团预期于截至2026年6月30日止6个月取得本公司权益股东应占亏损约人民币3.197亿元，较2025年同期的亏损约人民币8800万元增加约263.5%。本公司拥有充足的在手现金，可支持本公司运营至2029年。于2026年6月30日，本集团现金及现金等价物、定期存款、可转让存单、结构性存款及理财产品约为人民币23.05亿元。研发开支大幅增加主要由于本集团对推进其全面代谢性疾病产品管线的战略承诺。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1483596.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01672","BK1574","BK1515","01477","BK1191","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195243685","title":"歌礼制药-B发布盈利预警：2026年上半年预亏约3.20亿元，研发投入同比增约132.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1195243685","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195243685?lang=zh_cn&edition=full","pubTime":"2026-08-21 20:06","pubTimestamp":1787313993,"startTime":"0","endTime":"0","summary":"2026年8月21日，歌礼制药-B发布盈利预警称，预计截至2026年6月30日止六个月归属于公司权益股东的亏损约为3.20亿元，较2025年同期亏损0.88亿元扩大约263.5%。公司表示，亏损增加主要源于研发开支的显著上升。报告期内，研发开支约为3.42亿元，较2025年同期的1.47亿元增长约132.7%。截至2026年6月30日，集团持有的现金及现金等价物、定期存款、可转让存单、结构性存款及理财产品合计约23.05亿元，公司称该资金可支持运营至2029年。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661262114","title":"歌礼制药-B(01672.HK)获纳入恒生综合指数 有望成为港股通标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2661262114","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661262114?lang=zh_cn&edition=full","pubTime":"2026-08-21 18:48","pubTimestamp":1787309328,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01672","BK1161","BK1574","01477","BK1515","HSCI","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136215004","title":"歌礼制药宣布在美国启动两项肥胖症治疗I期临床研究：分别为每月一次的胰淀素受体肽激动剂Asc36及每月一次的Asc36与GLP-1R/GIPR肽激动剂Asc35联合制剂Asc36_35Fdc","url":"https://stock-news.laohu8.com/highlight/detail?id=1136215004","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136215004?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:05","pubTimestamp":1786359910,"startTime":"0","endTime":"0","summary":"歌礼制药-B（ASCLETIS-B）近日宣布，已在美国启动两项针对肥胖症治疗的I期临床研究。这两项研究分别聚焦于两款每月一次的注射制剂：其一为胰淀素受体肽激动剂Asc36；另一款则是Asc36与GLP-1R/GIPR肽激动剂Asc35的联合制剂，命名为Asc36_35Fdc。此举标志着该公司在代谢疾病领域，特别是肥胖症治疗的研发进程中，迈出了关键性的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01672","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135784758","title":"歌礼制药-B（01672）宣布在美启动两项肥胖症I期临床试验 涉及月度至季度长效多肽新药","url":"https://stock-news.laohu8.com/highlight/detail?id=1135784758","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135784758?lang=zh_cn&edition=full","pubTime":"2026-08-10 18:55","pubTimestamp":1786359330,"startTime":"0","endTime":"0","summary":"2026年8月10日，歌礼制药-B发布自愿性公告称，公司已获美国食品药品监督管理局新药临床试验申请批准，并在美国启动两项针对肥胖症的I期临床研究，药物均基于公司自研的AISBDD及ULAP技术平台。由胰淀素受体激动多肽ASC36与GLP-1R/GIPR双靶点激动多肽ASC35组成；歌礼制药-B表示，此次在肥胖症领域同步推进三项I期临床试验，成为公司2026年多肽长效管线的重要里程碑。公司管理层将持续披露项目进展。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658698026","title":"歌礼制药-B(01672)在美国启动两项治疗肥胖症的I期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2658698026","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658698026?lang=zh_cn&edition=full","pubTime":"2026-08-10 18:53","pubTimestamp":1786359237,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，在获得美国食品药品监督管理局新药临床试验申请批准后，其已在美国启动了两项治疗肥胖症的I期研究：每月一次至每季度一次的新一代胰淀素受体激动剂多肽ASC36，以及ASC36和GLP-1R/GIPR 双靶点激动剂多肽ASC35的皮下固定剂量复方月注射剂ASC36_35FDC。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478093.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1191","01672","BK1515","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657693089","title":"港股异动 | 创新药概念多数走高 创新药企陆续迎业绩窗口 后续学术会议有望带来密集催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2657693089","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657693089?lang=zh_cn&edition=full","pubTime":"2026-08-07 11:24","pubTimestamp":1786073069,"startTime":"0","endTime":"0","summary":"消息面上，近期多家创新药企业陆续发布业绩相关公告。从百济神州净利润同比增超6倍，到药明康德大幅上调全年收入指引，再到信达生物、荣昌生物各自兑现增长逻辑，创新药产业链正迎来\"业绩落地+催化密集\"的共振窗口。值得一提的是，海外顶级医学会议临床数据披露有望成为短期核心催化。其次，该行长期看好国产创新药发展趋势，行业景气度向上，出海持续演绎，后续学术会议陆续召开，临床数据有望读出，带来密集催化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477168.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359202008.SGD","IBBQ","LU1720050803.USD","01672","LU0979878070.USD","LU0039217434.USD","BK1515","LU0348735423.USD","LU0456846285.SGD","LU0572944931.SGD","LU0823426308.USD","LU1242518931.SGD","LU0043850808.USD","LU1794554557.SGD","LNGR","06978","BK1161","02269","09688","KCAI","SG9999002463.SGD","02268","07666","BK1521","159992","LU0327786744.USD","LU0516422366.SGD","LU0823426480.USD","LU0326950275.SGD","LU0359201612.USD","LU0856984785.SGD","BK1574","LU1880383366.USD","LU0181495838.USD","LU0417516902.SGD","LU2039709279.SGD","LU3063872942.SGD","MEDX","KURE","LU0417516738.SGD","BK1588","SG9999002562.SGD","LU0307460666.USD","LU0051755006.USD","LU0348825331.USD","LU0708995583.HKD","BK1589","VXUS","LU0819121731.USD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656587458","title":"【券商聚焦】东吴证券维持歌礼制药（01672）买入评级 指核心管线获双重催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2656587458","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656587458?lang=zh_cn&edition=full","pubTime":"2026-08-04 14:11","pubTimestamp":1785823914,"startTime":"0","endTime":"0","summary":"金吾财讯 | 东吴证券发布研报指，歌礼制药-B 核心品种ASC30已获美国FDA的III期临床批准，正式启动全球III期临床项目。核心管线进入注册临床关键阶段与后端创新管线数据亮眼，构成双重催化。此外，公司截至2025年年报的现金及现金等价物达14.4亿元人民币，为ASC30的III期临床推进提供了坚实的资金保障。东吴证券维持对歌礼制药2026至2028年营业收入预测，分别为0.46亿元、0.87亿元和1.36亿元人民币，维持“买入”评级。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987432","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","601555","01672","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140614009","title":"歌礼制药-B2026年7月股份变动月报表，股本持续调整","url":"https://stock-news.laohu8.com/highlight/detail?id=1140614009","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140614009?lang=zh_cn&edition=full","pubTime":"2026-08-04 12:20","pubTimestamp":1785817259,"startTime":"0","endTime":"0","summary":"歌礼制药-B于2026年8月4日披露了截至2026年7月31日的股份变动月报表。根据公告，公司本月法定/注册股本未发生变化，仍为7,000,000,000股普通股，每股面值0.0001美元，法定/注册股本总额维持在700,000美元。截至2026年7月31日，公司股本总数为1,057,769,055股。在购回及注销方面，公司于2026年6月29日至7月30日期间合计回购2,145,000股普通股并计划注销但截至报告期末尚未注销；另外，7月21日公司注销了此前回购共计800,000股和8,586,000股普通股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656589606","title":"歌礼制药-B早盘涨逾5% GLP-1口服小分子ASC30启动全球III期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2656589606","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656589606?lang=zh_cn&edition=full","pubTime":"2026-08-04 10:55","pubTimestamp":1785812100,"startTime":"0","endTime":"0","summary":"8月3日，歌礼制药宣布，每日一次口服小分子GLP-1已获得美国食品药品监督管理局的III期临床研究批准。ASC30是歌礼口服小分子肥胖症治疗管线组合中的核心支柱。公司已针对ASC30长期体重管理适应症启动了一项全球III期临床项目，将在美国、欧洲和加拿大开展两项关键临床试验，将入组约4，600名肥胖或超重受试者。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-04/doc-inimchzv2245265.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01477","01672","III","GLP","BK1191","BK1574","BK1161","BK1515","BK4144","BK4590","JDOC","BK4134"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascletis.com","stockEarnings":[{"period":"1week","weight":-0.0067},{"period":"1month","weight":0.0937},{"period":"3month","weight":-0.0143},{"period":"6month","weight":-0.2826},{"period":"1year","weight":-0.2674},{"period":"ytd","weight":-0.0931}],"compareEarnings":[{"period":"1week","weight":-0.0138},{"period":"1month","weight":-0.0247},{"period":"3month","weight":0.0101},{"period":"6month","weight":-0.0211},{"period":"1year","weight":-0.0051},{"period":"ytd","weight":-0.0163}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"歌礼制药有限公司是一家主要从事医药产品研发、生产和销售的投资控股公司。该公司专注于病毒性疾病、非酒精性脂肪性肝炎（NASH）或原发性胆汁性胆管炎（PBC）及肿瘤领域。该公司的产品管线包括用于慢性乙肝功能性治愈的ASC22、用于呼吸道合胞病毒（RSV）的ASC10、用于人类免疫缺陷病毒（HIV）功能性治愈的ASC22、用於新冠肺炎的ASC10及ASC11、用於NASH的ASC41、用於PBC的ASC42、用于实体瘤的ASC61、用于中、重度痤疮的ASC40等。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.146882},{"month":2,"riseRate":0.75,"avgChangeRate":0.100059},{"month":3,"riseRate":0.375,"avgChangeRate":-0.044472},{"month":4,"riseRate":0.375,"avgChangeRate":-0.053142},{"month":5,"riseRate":0.375,"avgChangeRate":-0.01034},{"month":6,"riseRate":0.375,"avgChangeRate":-0.053675},{"month":7,"riseRate":0.5,"avgChangeRate":0.001982},{"month":8,"riseRate":0.375,"avgChangeRate":-0.008209},{"month":9,"riseRate":0.222222,"avgChangeRate":-0.061422},{"month":10,"riseRate":0.5,"avgChangeRate":-0.023171},{"month":11,"riseRate":0.875,"avgChangeRate":0.185422},{"month":12,"riseRate":0.5,"avgChangeRate":0.087327}],"exchange":"SEHK","name":"歌礼制药-B","nameEN":"ASCLETIS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供歌礼制药-B(01672)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"歌礼制药-B,01672,歌礼制药-B股票,歌礼制药-B股票老虎,歌礼制药-B股票老虎国际,歌礼制药-B行情,歌礼制药-B股票行情,歌礼制药-B股价,歌礼制药-B股市,歌礼制药-B股票价格,歌礼制药-B股票交易,歌礼制药-B股票购买,歌礼制药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供歌礼制药-B(01672)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}